骨壊死治療の世界市場

骨壊死治療の世界市場は2030年までに3億2,540万米ドルに達する見込み

2023年に2億6,030万米ドルと推定される骨壊死治療の世界市場は、分析期間2023-2030年にCAGR 3.2%で成長し、2030年には3億2,540万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである非ステロイド性抗炎症薬は、CAGR 4.3%を記録し、分析期間終了までに1億2,390万米ドルに達すると予測されます。コレステロール低下薬セグメントの成長率は、分析期間中CAGR 2.6％と推定されます。

米国市場は7,090万米ドルと推定、中国はCAGR 6.4％で成長予測

米国の骨壊死治療市場は2023年に7,090万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6,760万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.5％と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界の骨壊死治療市場- 主要動向と促進要因のまとめ

骨壊死は、血管壊死、無菌性壊死、虚血性骨壊死とも呼ばれ、血液供給不足による骨細胞の死滅を特徴とする病態であり、一般に大腿骨などの長骨の末端に影響を及ぼします。この病気は、関節の近くで起こると、関節の崩壊や関節炎につながる可能性があります。骨壊死の正確な原因は不明ですが、大腿骨上部や足首の骨によく起こります。診断は通常、整形外科医がX線やMRIなどの画像診断技術を用いて行います。骨壊死の重症度と進行度は、罹患した骨の部位、病気の程度、体の骨再生能力によって異なります。場合によっては骨の崩壊に至り、激しい痛みや関節機能の喪失を引き起こします。顎骨壊死（ONJ）は、この病態の特殊な形態で、ビスフォスフォネート静注療法を受けているがん患者にしばしば発症し、歯科処置後に起こり、骨が露出し、その後骨死に至ることもあります。

骨壊死の管理には、疾患の進行を止め、疼痛を緩和し、可動性を高めることを目的とした外科的治療と非外科的治療の両方があります。非外科的治療には、骨量の減少を抑えるビスフォスフォネート系薬剤や、疼痛や炎症を抑える非ステロイド性抗炎症薬などの薬剤が用いられることが多いです。コレステロールを低下させることで知られるスタチン系薬剤も、骨への血流を改善することで効果を発揮します。理学療法は重要な役割を果たし、関節の可動性と筋力を維持するために、温熱や氷の治療、鍼治療、負荷の少ない運動などの技術を用います。松葉杖や装具のような補助器具は、患部の骨からストレスを取り除くために推奨されます。画像検査や血液検査による定期的なモニタリングで治療効果を確認し、必要に応じて計画を調整します。重症の場合は、死んだ骨組織を除去して関節機能を回復させるために外科的介入が必要になることもあります。

いくつかの要因が骨壊死治療の成長と進歩を促進しています。MRIなどの診断技術の向上により、より早期かつ正確な発見が可能となり、治療成績が向上しました。患者やヘルスケア提供者の意識と教育の向上により、専門的ケアへの需要が高まっています。個別化医療を含むカスタマイズされた治療計画は、患者のアドヒアランスと治療成績を向上させる。遠隔医療の統合により、特に遠隔地における骨壊死の継続的な管理が容易になった。ヘルスケア政策の変化と保険適用の改善は、先進的治療の導入を促進します。学術機関、ヘルスケアプロバイダー、製薬会社の連携が、新たな治療法の研究開発を促進します。これらの進歩は総体的に、テクノロジーと患者中心の戦略を重視し、ケアとアウトカムを向上させるという、情勢を形成しています。

調査対象企業の例（全46件）

• Amgen Inc
• BioSenic SA
• Dr. Reddy's Laboratories
• Enzo Biochem Inc
• Exactech, Inc.
• Integra lifesciences Corp.
• J&J MedTech-Medical Devices Business Services, Inc
• Medacta International SA
• Merck & Co. Inc
• Novartis AG
• Pharmanovia
• Regrow Biosciences Pvt Ltd.
• Teva Pharmaceutical Industries Ltd
• Vericel Corporation
• Zimmer Biomet Holdings, Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Osteonecrosis Treatment Market to Reach US$325.4 Million by 2030

The global market for Osteonecrosis Treatment estimated at US$260.3 Million in the year 2023, is expected to reach US$325.4 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. NSAIDS Drugs, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$123.9 Million by the end of the analysis period. Growth in the Cholesterol-Lowering Drugs segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$70.9 Million While China is Forecast to Grow at 6.4% CAGR

The Osteonecrosis Treatment market in the U.S. is estimated at US$70.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$67.6 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Osteonecrosis Treatment Market - Key Trends and Drivers Summarized

Osteonecrosis, also known as avascular necrosis, aseptic necrosis, or ischemic bone necrosis, is a condition characterized by the death of bone cells due to insufficient blood supply, commonly affecting the ends of long bones such as the femur. This disease can lead to joint collapse and arthritis if it occurs near a joint. The exact cause of osteonecrosis is unclear, but it frequently impacts the upper femur and ankle bones. Diagnosis is typically made by orthopedic surgeons using imaging techniques like X-rays or MRI. The severity and progression of osteonecrosis vary based on the affected bone area, the extent of the disease, and the body's ability to regenerate bone. In some cases, the disease leads to bone collapse, causing severe pain and loss of joint function. Osteonecrosis of the Jaw (ONJ), a specific form of this condition, often affects cancer patients receiving intravenous bisphosphonate therapy and can occur after dental procedures, leading to exposed bone and subsequent bone death.

Management of osteonecrosis includes both surgical and nonsurgical options aimed at halting disease progression, relieving pain, and enhancing mobility. Nonsurgical treatments often involve medications such as bisphosphonates, which help reduce bone loss, and NSAIDs to manage pain and inflammation. Statins, known for lowering cholesterol, may also aid by improving blood flow to the bone. Physical therapy plays a crucial role, employing techniques like heat and ice treatments, acupuncture, and low-impact exercises to maintain joint mobility and muscle strength. Assistive devices like crutches or braces are recommended to offload stress from the affected bones. Regular monitoring through imaging and blood tests ensures the treatment's efficacy and adjusts plans as needed. In more severe cases, surgical intervention may be required to remove dead bone tissue and restore joint function.

Several factors are driving the growth and advancements in osteonecrosis treatment. Improved diagnostic technologies such as MRI allow for earlier and more accurate detection, enhancing treatment outcomes. Increased awareness and education among patients and healthcare providers have led to a higher demand for specialized care. Customized treatment plans, including personalized medicine, improve patient adherence and outcomes. The integration of telemedicine facilitates continuous management of osteonecrosis, especially in remote areas. Changes in healthcare policies and better insurance coverage encourage the adoption of advanced treatments. Collaborations between academic institutions, healthcare providers, and pharmaceutical companies drive research and development of new therapies. These advancements collectively shape the evolving landscape of osteonecrosis treatment, emphasizing technology and patient-centered strategies to enhance care and outcomes.

Select Competitors (Total 46 Featured) -

• Amgen Inc
• BioSenic SA
• Dr. Reddy's Laboratories
• Enzo Biochem Inc
• Exactech, Inc.
• Integra lifesciences Corp.
• J&J MedTech- Medical Devices Business Services, Inc
• Medacta International SA
• Merck & Co. Inc
• Novartis AG
• Pharmanovia
• Regrow Biosciences Pvt Ltd.
• Teva Pharmaceutical Industries Ltd
• Vericel Corporation
• Zimmer Biomet Holdings, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Osteonecrosis Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Osteonecrosis Propels Treatment Market Growth
  • Advances in Diagnostic Technologies Expand Addressable Market
  • Increased Healthcare Expenditure Spurs Market Growth
  • Aging Population Generates Demand for Osteonecrosis Treatments
  • Minimally Invasive Treatments Grow in Popularity
  • The Role of Regenerative Medicine in Osteonecrosis Treatment: A Review
  • Increasing Awareness of Bone Health. Here is the Story
  • Personalized Medicine Strengthens Business Case for Targeted Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Osteonecrosis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Osteonecrosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Osteonecrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for NSAIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for NSAIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Cholesterol-Lowering Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Cholesterol-Lowering Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Cholesterol-Lowering Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Blood Thinners by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Blood Thinners by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Blood Thinners by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Joint Replacement Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Joint Replacement Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Joint Replacement Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• JAPAN
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• CHINA
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• EUROPE
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Osteonecrosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Osteonecrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• FRANCE
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• GERMANY
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Osteonecrosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Osteonecrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• INDIA
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: India 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: India 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: India 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Osteonecrosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Osteonecrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Osteonecrosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Osteonecrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030
• AFRICA
  • Osteonecrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Osteonecrosis Treatment by Drug Type - NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Osteonecrosis Treatment by Drug Type - Percentage Breakdown of Value Sales for NSAIDS, Cholesterol-Lowering Drugs, Blood Thinners and Other Drug Types for the Years 2014, 2024 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Osteonecrosis Treatment by End-Use - Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Osteonecrosis Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Specialty Clinics End-Use and Homecare End-Use for the Years 2014, 2024 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Osteonecrosis Treatment by Therapy Type - Joint Replacement Surgery and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Osteonecrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Joint Replacement Surgery and Stem Cell Therapy for the Years 2014, 2024 & 2030

IV. COMPETITION